Immune-Stimulating Antibody Conjugate (ISAC) Development Service
Overview Solution Application What We Can Offer? Workflow Our Advantages Published Data FAQs
Are you currently facing the challenges of systemic toxicity from immunotherapies, or struggling to treat "immune-cold" tumors that don't respond to conventional treatments? Creative Biolabs' Immune-stimulating Antibody Conjugate (ISAC) service helps you overcome these hurdles by accelerating drug discovery and developing highly specific, potent therapeutics through our innovative bioconjugation technology. Our ISACs deliver immune-activating payloads directly to the tumor microenvironment, minimizing off-target effects and unleashing a targeted, powerful anti-cancer immune response.
Virus-Like Drug Conjugates (VDC)
Immune-stimulating Antibody Conjugates (ISACs) represent a significant advancement in targeted cancer immunotherapy. These biological therapeutics integrate monoclonal antibody precision with high-potency immunostimulants. The primary goal of an ISAC is to deliver an immune stimulant directly to the tumor microenvironment. This localized delivery minimizes the severe systemic toxicity often seen with traditional immunomodulatory agents, while maximizing the therapeutic effect at the site of the disease. The core function of ISACs is to convert "immune-cold" tumors, which are often resistant to checkpoint inhibitors, into "immune-hot" tumors that can be effectively eliminated by the body's own immune system.
Fig.1 Operational principles of Antibody-based immunostimulatory agents (ABIs).1,3
Our Virus-Like Drug Conjugates (VDC) Solution
Creative Biolabs offers a diverse range of conjugation solutions to create highly effective ISACs, leveraging our deep expertise in linker chemistry and payload selection. We can conjugate antibodies to various immune-stimulating payloads, including:
-
Toll-Like Receptor (TLR) Agonists: These molecules bind to TLRs on the surface of immune cells such as dendritic cells and macrophages. The targeted delivery of these agonists, such as specific TLR7/8 or TLR9 agonists, initiates a powerful innate immune response, which is crucial for subsequent T cell-mediated anti-tumor activity.
-
STING Agonists: The Stimulator of Interferon Genes pathway constitutes a fundamental element of intrinsic defense mechanisms. By activating this pathway directly within the tumor microenvironment with a targeted agonist, we can induce a strong and localized Type I interferon response, which is highly effective in promoting anti-tumor immunity and overcoming resistance to other immunotherapies.
-
Cytokines: We can also conjugate antibodies to potent cytokines, such as IL-12 or IL-15. These primary immunomodulators are indispensable for alleviating T cell depletion, enhancing expansion and cytolytic potential of effector cells, and augmenting collective antitumor immunity.
-
Immunogenic Cell Death (ICD) Inducers: This class of payloads induces a unique form of tumor cell death that alerts the immune system to the presence of cancer, further enhancing the anti-tumor response. By conjugating ICD inducers to a tumor-specific antibody, we can create a powerful and self-amplifying therapeutic effect.
Application
The application of Immune-stimulating Antibody Conjugates is centered on their ability to precisely modulate the immune system to fight cancer. Key applications include:
-
Treating Immune-Cold Tumors: By delivering immune agonists directly to tumors lacking immune cell infiltration, ISACs can reprogram the tumor microenvironment, making it susceptible to immune attack.
-
Combination Therapies: ISACs can be combined with other cancer treatments, such as checkpoint inhibitors (e.g., anti-PD-1 therapies) and chemotherapy, to achieve synergistic effects and overcome treatment resistance.
-
Creating Immunological Memory: The robust immune response triggered by ISACs can lead to long-lasting immunological memory, protecting the patient from tumor recurrence.
-
Minimizing Systemic Toxicity: The targeted nature of ISACs allows for potent immune activation at the tumor site while minimizing the risk of widespread, off-target toxicity.
Contact Us About Bioconjugation Services
What We Can Offer?
Creative Biolabs is uniquely positioned at the forefront of bioconjugation and targeted drug delivery innovation. Our team of expert biologists, chemists, and engineers brings over two decades of collective experience in developing sophisticated delivery solutions. We offer a comprehensive suite of products and services tailored to your needs.
Ready-to-Use Products
We provide a comprehensive catalog of pre-formulated delivery systems and validated targeting modules, ready for your research and development needs.
Customized Services
Our bespoke service allows us to develop tailored ISACs from concept to validation, precisely meeting your project's unique specifications. This includes custom antibody/payload synthesis and conjugation, as well as optimization of ISAC characteristics for specific tumor types.
Conjugation Services
We have deep expertise in conjugating selected ligands or payloads to various delivery platforms, including antibodies.
Pre-Clinical Validation
We offer comprehensive in vitro and in vivo testing to assess targeting efficiency, cellular uptake, biodistribution, and therapeutic efficacy.
Comprehensive Scientific Support
Partner with us to leverage our deep scientific knowledge, state-of-the-art facilities, and rigorous quality control for your targeted delivery projects, from experimental design to data analysis.
Workflow
Why Choose Us?
Partnering with Creative Biolabs means choosing a path to accelerated drug development, enhanced therapeutic efficacy, and a significant reduction in off-target effects. Our commitment to innovation and scientific excellence ensures that your therapeutic agents reach their targets with unprecedented precision, unlocking new possibilities for disease treatment.
Proven Expertise
Our team of highly specialized biologists, chemists, and engineers possesses deep scientific knowledge in bioconjugation, drug delivery systems, and targeting module development.
Innovative Technology
We leverage state-of-the-art platforms for module synthesis, conjugation, and characterization, ensuring optimal results.
Tailored Customization & Flexibility
We offer customized antibody/payload design and delivery system optimization to perfectly align with your therapeutic goals.
Rigorous Quality & Reliability
Our commitment to scientific rigor and a meticulous quality assurance process ensures reliable, reproducible, and high-quality results for your critical projects.
Contact Our Experts Today
Published Data
Fig.2 Architecture of the STING agonist immunostimulatory antibody conjugate with physicochemical characterization and cellular-level bioactivity.2,3
In a key study, researchers developed a next-generation ISAC, to overcome the limitations of existing HER2-targeted therapies and STING agonists. The ISAC was synthesized by linking a STING agonist to an anti-HER2 antibody using a stable, noncleavable linker. The final construct had a drug-to-antibody ratio (DAR) of 5.7 and demonstrated excellent stability in both PBS and plasma. While the binding affinity of the antibody component was slightly reduced, the ISAC was still effectively internalized by tumor cells. In vivo studies in mouse models revealed that the ISAC was well-tolerated and showed potent anti-tumor activity. The mechanism was found to be mediated by the STING pathway, which activated both immune and tumor cells, with immune cell activation playing the dominant role. This dual activation led to a sustained anti-tumor response and the development of long-lasting immunological memory. Safety evaluations confirmed the ISAC did not cause significant hepatic or renal toxicity, supporting its potential for clinical development as a promising new cancer immunotherapy.
FAQs
Q: How do ISACs compare to Antibody-Drug Conjugates (ADCs)?
A: While both technologies use antibodies to deliver a payload, their mechanisms and goals are different. ADCs deliver a cytotoxic chemotherapy agent to directly kill cancer cells. ISACs, on the other hand, deliver an immune-stimulating agent to activate the patient's own immune system, enabling it to recognize and destroy the cancer cells. This leads to a more durable and systemic anti-tumor effect.
Q: How can you ensure the specificity and efficacy of the ISAC?
A: We employ a multi-step approach to ensure both specificity and efficacy. It begins with the selection of a highly specific antibody and a potent immune-stimulating payload. The conjugation process is carefully controlled to maintain the integrity of both components. Finally, we conduct rigorous in vitro and in vivo studies to validate the ISAC's targeting, cellular internalization, and immune-activating capabilities.
Q: What types of tumors can ISACs be used to treat?
A: ISACs can be designed to target a wide range of tumors, particularly those with well-defined surface antigens. A major advantage of this technology is its potential to treat "immune-cold" tumors that are typically unresponsive to other immunotherapies, as it can effectively transform their microenvironment.
Q: Is the immune response generated by ISACs limited to the targeted tumor?
A: While the initial activation is localized to the targeted tumor, the resulting immune response is systemic. Activated immune cells present tumor antigens to the wider immune system, leading to the generation of a powerful and broad anti-tumor response that can target both primary and metastatic tumors, creating immunological memory.
Q: What are the key advantages of using ISACs over systemic administration of immune agonists?
A: The main advantage is the significant reduction in systemic toxicity. By delivering the immune agonist directly to the tumor microenvironment, ISACs allow for a much higher concentration of the therapeutic agent where it is needed most, without the widespread and often severe side effects associated with systemic administration.
Creative Biolabs' Immune-stimulating Antibody Conjugate (ISAC) service offers a powerful and innovative approach to cancer immunotherapy. We provide a complete suite of solutions, from custom design and synthesis to rigorous preclinical validation, helping you to develop highly effective, targeted therapeutics that minimize toxicity and unlock new possibilities for disease treatment.
Connect with our experts for project-specific consultation and detailed insights.
References
-
Zhao, Ren-Jie, and Xing-Xing Fan. "Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy." International journal of molecular sciences vol. 26,4 1440. 8 Feb. 2025, https://doi.org/10.3390/ijms26041440
-
Wu, Gang et al. "Next-Generation HER-2 Tumor-Targeted Delivery of the STING Agonist Immune-Stimulating Antibody Conjugate (ISAC) Improves Anticancer Efficacy and Induces Immunological Memory." MedComm vol. 6,7 e70254. 2 Jul. 2025, https://doi.org/10.1002/mco2.70254
-
Distributed under Open Access license CC BY 4.0, without modification.
Our services are For Research Use Only. We do not provide services to individuals.
